-
Europe’s Largest Clinical Trial Sponsors Are Getting Better at Reporting Results Opens in a new window)
The 26 research institutions have run nearly 4,600 trials testing medicines and, so far, 641 sets of results have been made available. -
NICE Recommends First New Sickle Cell Disease Treatment in 20 Years Opens in a new window)
NICE has announced on Tuesday that for the first time in 20 years, a new treatment will be made available on the NHS for sickle cell disease.Comments
-
Germany Decides On Added Benefit Of Gilead’s Veklury For COVID-19 Opens in a new window)
The body in charge of pricing and reimbursement in Germany has downgraded the extent of additional benefit offered by Gilead’s Veklury for treating COVID-19 patients.Comments
-
European Health Union: Towards a reform of EU's pharmaceutical legislation
As part of its work to create a future-proof and crisis-resilient regulatory framework for the pharmaceutical sector, the Commission has published a public consultation on the revision of the EU's pharmaceutical legislation.Comments
-
Oslo Medicines Initiative
At the technical briefing, a new vision for collaboration between the public and private sectors was put forward to provide better access to safe, effective, novel, high-priced medicines.Comments
-
How the Oslo Medicines Initiative can Tackle the Ever-Increasing Prices for Medicines and Vaccines Opens in a new window)
Undeniably, COVID19 illustrates and emphasizes the urgent need to further increase transparency in pharmaceuticals, and to strengthen collaboration amongst Member States.Comments
-
U.K. Government Launches a New System to Monitor Clinical Trial Reporting Opens in a new window)
The U.K. government is now tracking whether clinical trial sponsors are reporting results, the latest sign that transparency campaigns are forcing greater disclosure by universities and companies.Comments
-
Wider Use of SGLT2 Inhibitors for CVD Recommended by NICE Opens in a new window)
NICE has updated its guidelines on the management of type 2 diabetes, recommending wider use of SGLT2 inhibitors in those with or at high-risk of cardiovascular disease (CVD).Comments
-
Essex Baby Given £1.79M Drug Makes 'Huge Progress' Opens in a new window)
A baby who received the world's most expensive drug four weeks ago has made "huge" progress, his parents said.Comments
-
Cholesterol-Busting Drug Could Save Thousands of Lives
The health service will make the new treatment, inclisiran, available to 300,000 patients with high cholesterol and a history of cardiovascular disease over the next three years.Comments
-
EU and AstraZeneca Reach Deal to End Vaccine Row Opens in a new window)
The EU and UK-Swedish drug-maker AstraZeneca have settled a row over a shortfall in coronavirus vaccines that affected the European rollout earlier this year.Comments
-
AstraZeneca Reaches Settlement With EU on COVID-19 Vaccine Delivery Opens in a new window)
The dispute plunged the European Union into crisis earlier this year as states, under pressure to speed up vaccinations, scrambled for shots. It also caused a public relations crisis for AstraZeneca, which is led by Frenchman Pascal Soriot.Comments
-
EMA Lays Out Plans For Routine Use Of Real-World Evidence Opens in a new window)
A panel of regulators overseeing the implementation of several big data projects within the EU medicines network has given details of real-world evidence integration pilots to be undertaken next year.Comments
-
NICE Recommends Novartis’ Cosentyx for Children with Severe Psoriasis Opens in a new window)
The National Institute for Health and Care Excellence (NICE) has recommended Novartis’ interleukin-17A (IL-17A) inhibitor Cosentyx (secukinumab) for the treatment of children and young people with moderate-to-severe psoriasis.Comments
-
Zolgensma Provides No Proven Benefit Over Spinraza In SMA, Says German HTA Opens in a new window)
IQWiG, Germany’s health technology appraisal institute, has found that Novartis’s gene therapy Zolgensma offers no additional benefit compared with Biogen’s Spinraza for treating spinal muscular atrophy.Comments
Comments